{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:06:54Z","timestamp":1791421614656,"version":"4.3.3"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study aimed to report a case who was treated with corticosteroids and anti- parasitic agents for ocular toxoplasmosis, but who progressed to acute retinal necrosis, and finally retinal detachment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>A 42-year-old man presented to the ophthalmology clinic with a 1-month history of progressive blurred vision and floaters in his right eye. His best visual acuity (VA) was 20\/20 in both eyes. The anterior segment was unremarkable. Funduscopic examination of the right eye revealed active lesions of whitish foci of chorioretinitis with surrounding edema along the superonasal vessels, and retinal vasculitis with perivascular sheathing. Serologic testing was positive for <jats:italic>Toxoplasma gondii<\/jats:italic> IgM and IgG, but negative for other virus- and syphilis infections. Ocular toxoplasmosis was diagnosed. Corticosteroids and anti-parasitic agents were given simultaneously, but his right eye VA became 20\/100. Funduscopic examination revealed retinal necrosis with localized retinal breaks. We immediately performed focal photocoagulation, however, his right eye progressed to retinal detachment and required vitrectomy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Early administration of systemic corticosteroids in patients with acquired acute ocular toxoplasmosis may lead to complications that impair vision. Intensive observation should be arranged after corticosteroid use.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.843050","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T04:30:51Z","timestamp":1656477051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Corticosteroids in Treating Acute Ocular Toxoplasmosis in an Immunocompetent Patient: A Case Report"],"prefix":"10.3389","volume":"9","author":[{"given":"Hung-Yi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ju Annabelle","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03520050034024","article-title":"Ocular toxoplasmosis.","volume":"272","author":"Frenkel","year":"1994","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/00055735-200312000-00011","article-title":"Ocular manifestations of toxoplasmosis.","volume":"14","author":"Rothova","year":"2003","journal-title":"Curr Opin Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/IIO.0b013e31822d663b","article-title":"Ocular toxoplasmosis: advances in detection and treatment.","volume":"51","author":"Englander","year":"2011","journal-title":"Int Ophthalmol Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1089\/jop.2015.0059","article-title":"Current therapy of acquired ocular toxoplasmosis: a review.","volume":"31","author":"Lima","year":"2015","journal-title":"J Ocular Pharmacol Therapeut."},{"key":"B5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1590\/s0074-02762009000200030","article-title":"Ocular toxoplasmosis: an update and review of the literature.","volume":"104","author":"Commodaro","year":"2009","journal-title":"Mem Inst Oswaldo Cruz."},{"key":"B6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/09273948.2011.564068","article-title":"Clinical manifestations of ocular toxoplasmosis.","volume":"19","author":"Delair","year":"2011","journal-title":"Ocular Immunol Inflamm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3109\/09273948.2015.1051360","article-title":"Ocular toxoplasmosis.","volume":"23","author":"Cunningham","year":"2015","journal-title":"Ocular Immunol Inflamm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1442-9071.2012.02838.x","article-title":"Ocular toxoplasmosis II: clinical features, pathology and management.","volume":"41","author":"Butler","year":"2013","journal-title":"Clin Exp Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1442-9071.2012.02821.x","article-title":"Ocular toxoplasmosis I: parasitology, epidemiology and public health.","volume":"41","author":"Furtado","year":"2013","journal-title":"Clin Exp Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000363141","article-title":"Ocular toxoplasmosis: recent aspects of pathophysiology and clinical implications.","volume":"52","author":"Pleyer","year":"2014","journal-title":"Ophthalmic Res."},{"key":"B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000449169","article-title":"Recent developments in the diagnosis and treatment of ocular toxoplasmosis.","volume":"57","author":"Ozgonul","year":"2017","journal-title":"Ophthalmic Res."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100882","article-title":"Pathogenesis of ocular toxoplasmosis.","volume":"81","author":"Smith","year":"2021","journal-title":"Prog Retinal Eye Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00347-009-2049-3","article-title":"[Diagnostics and differential diagnosis of acute retinal necrosis].","volume":"106","author":"Pleyer","year":"2009","journal-title":"Ophthalmologe."},{"key":"B14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/archopht.123.6.844","article-title":"Ocular tuberculosis.","volume":"123","author":"Thompson","year":"2005","journal-title":"Arch Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3109\/09273948.2015.1057599","article-title":"Fulminant Ocular Toxoplasmosis: the Hazards of Corticosteroid Monotherapy.","volume":"24","author":"Oray","year":"2016","journal-title":"Ocul Immunol Inflamm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/s0002-9394(02)01526-x","article-title":"An update on current practices in the management of ocular toxoplasmosis.","volume":"134","author":"Holland","year":"2002","journal-title":"Am J Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0002-9394(14)74456-3","article-title":"Therapy for ocular toxoplasmosis.","volume":"115","author":"Rothova","year":"1993","journal-title":"Am J Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S0161-6420(92)31873-1","article-title":"Trimethoprim-sulfamethoxazole therapy for ocular toxoplasmosis.","volume":"99","author":"Opremcak","year":"1992","journal-title":"Ophthalmology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3109\/09273948.2013.779724","article-title":"Therapy for ocular toxoplasmosis\u2013the future.","volume":"21","author":"Garweg","year":"2013","journal-title":"Ocular Immunol Inflamm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ophtha.2012.07.061","article-title":"Interventions for toxoplasma retinochoroiditis: a report by the American Academy of Ophthalmology.","volume":"120","author":"Kim","year":"2013","journal-title":"Ophthalmology."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007417.pub","article-title":"Corticosteroids as adjuvant therapy for ocular toxoplasmosis.","volume":"1","author":"Jasper","year":"2017","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.843050\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T04:30:54Z","timestamp":1656477054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.843050\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":21,"alternative-id":["10.3389\/fmed.2022.843050"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.843050","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"article-number":"843050"}}